Lorrain Daniel S. 4

What Happened

• Daniel S. Lorrain, Chief Scientific Officer of Contineum Therapeutics (CTNM), sold 4,170 shares on March 2, 2026.
• The weighted-average sale price was $15.01 per share, for total proceeds of approximately $62,585. This sale was executed under a pre-established 10b5-1 trading plan.

Key Details

• Transaction date: March 2, 2026. Prices reported as a weighted average $15.01; individual sale prices ranged $14.60–$15.41.
• Shares sold: 4,170. Estimated proceeds: $62,585.
• Shares owned following the transaction: Not specified in the information provided in this summary. (Check the full Form 4 for post-transaction holdings.)
• Footnotes: F1 — trade effected pursuant to a 10b5-1 plan adopted Sept 23, 2025. F2 — price is weighted average; breakdown by individual trade price available on request.
• Filing timeliness: Reported on the same day as the transaction (no late filing indicated).

Context

• The sale was made under a 10b5-1 plan, which is a pre-arranged trading program that allows insiders to sell shares at scheduled times and is commonly used to avoid questions about trading on material nonpublic information. Sales under such plans are generally considered routine; they do not by themselves indicate management sentiment about the company’s prospects.